Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29148790 | 0.88 | AMY1A (0.34) | — | |
| SCHEMBL1271011 | 0.85 | KDM4E (0.30) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL4428378 | 0.84 | — | — | |
| SCHEMBL7259993 | 0.81 | KDM4E (0.35) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL27910483 | 0.76 | MAPT (0.40) | KDM4EMAPTTDP1MEN1MAPK1 | |
| SCHEMBL28098902 | 0.76 | MAPT (0.40) | KDM4EMAPTTDP1MEN1MAPK1 | |
| SCHEMBL1275382 | 0.70 | MAOA (0.31) | — | |
| SCHEMBL28187477 | 0.70 | MAOA (0.31) | — | |
| SCHEMBL28306376 | 0.70 | MAOA (0.31) | — | |
| SCHEMBL28146959 | 0.70 | MAOA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-20160205925-A1 | ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2016-07-21 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| US-7850981-B2 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT, INC. (CA) | 2010-12-14 | — | — | US | disclosed |
| US-7753943-B2 | Reduced fluence rate PDT | QLT INC. (CA) | 2010-07-13 | — | — | US | disclosed |
| WO-2010069073-A1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | QLT INC. (CA) | 2010-06-24 | — | — | WO | disclosed |
| US-20100040546-A1 | Biological targeting compositions and methods of using the same | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-18 | — | — | US | disclosed |
| US-20090192209-A1 | Extended treatment of tumors through vessel occlusion with light activated drugs | LIGHT SCIENCES ONCOLOGY, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1377274-B1 | DRUG DELIVERY SYSTEM FOR PHOTOSENSITIZERS | QUADRA LOGIC TECH INC (CA) | 2008-10-15 | — | — | EP | disclosed |
| EP-1357946-B1 | PHOTODYNAMIC THERAPY WITH REDUCED FLUENCE RATE | QUADRA LOGIC TECH INC (CA) | 2008-03-26 | — | — | EP | disclosed |
| US-6599891-B2 | Administering to the subject an amount of a photosensitizer (PS) sufficient to allow said photosensitizer to localize in lesion; irradiating said lesion with light having a wavelength absorbed by said PS | QLT INC. (CA) | 2003-07-29 | — | — | US | disclosed |
| US-20030099596-A1 | Treatment of macular edema | BAUSCH HEALTH IRELAND LIMITED (IE) | 2003-05-29 | — | — | US | disclosed |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-20030083649-A1 | Method for reducing or preventing PDT related inflammation | VALEANT SP. Z.O.O. (PL) | 2003-05-01 | — | — | US | disclosed |
| US-20020183302-A1 | Method to prevent vision loss | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020173832-A1 | Reduced fluence rate PDT | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | BAUSCH HEALTH COMPANIES INC. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099596-A1 | Treatment of macular edema | VEGFA, PPOX, FLT4 | KDM4E 2230/4885ALDH1A1 3216/4885HPGD 583/4885 |
| US-20020183302-A1 | Method to prevent vision loss | VEGFA, ALDH1A2, PDE6C | KDM4E 3259/4885ALDH1A1 901/4885HPGD 252/4885 |
| US-20090192209-A1 | Extended treatment of tumors through vessel occlusion with light activated drugs | PTGIR, TEK, FLT4 | KDM4E 3181/4885ALDH1A1 1959/4885HPGD 76/4885 |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | LIPA, MLEC, ABCG2 | KDM4E 3305/4885ALDH1A1 2604/4885HPGD 2568/4885 |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | PIN1, PPOX, DHFR | KDM4E 1989/4885ALDH1A1 701/4885HPGD 738/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | KDM4E 3097/4885ALDH1A1 371/4885HPGD 172/4885 |
| US-20160205925-A1 | ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER | CUTA, POLR1C, PUF60 | KDM4E 3572/4885ALDH1A1 1405/4885HPGD 1070/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | KDM4E 4361/4885ALDH1A1 794/4885HPGD 318/4885 |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | ALDH1A2, AGER, CRY2 | KDM4E 3312/4885ALDH1A1 262/4885HPGD 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.